New drug combo aims to shrink tumors before breast cancer surgery
NCT ID NCT06144944
First seen Oct 31, 2025 · Last updated Apr 14, 2026 · Updated 23 times
Summary
This study is testing whether adding a drug called pyrotinib to standard chemotherapy works better than chemotherapy alone for people with a specific type of high-risk, early-stage breast cancer. The goal is to shrink the tumor as much as possible before surgery. About 160 participants will be randomly assigned to receive either the drug combination or just chemotherapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EARLY STAGE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Guangzhou, Guangdong, 510120, China
Conditions
Explore the condition pages connected to this study.